



Analysis of T-Cell Receptor Repertoire in Transplantation: Fingerprint of T Cell-mediated Alloresponse

Guangyao Tian, Mingqian Li* and Guoyue Lv*

Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, China

OPEN ACCESS

Edited by:

Yongxia Wu,
Medical University of South Carolina,
United States

Reviewed by:

Hong Lei,
The Affiliated Children's Hospital of
Xi'an Jiaotong University, China
Alexander Yermanos,
ETH Zürich, Switzerland

*Correspondence:

Guoyue Lv
lvgy@jlu.edu.cn
Mingqian Li
mingqianli@jlu.edu.cn

Specialty section:

This article was submitted to
Alloimmunity and Transplantation,
a section of the journal
Frontiers in Immunology

Received: 17 September 2021

Accepted: 22 December 2021

Published: 12 January 2022

Citation:

Tian G, Li M and Lv G (2022)
Analysis of T-Cell Receptor Repertoire
in Transplantation: Fingerprint of
T Cell-mediated Alloresponse.
Front. Immunol. 12:778559.
doi: 10.3389/fimmu.2021.778559

T cells play a key role in determining allograft function by mediating allogeneic immune responses to cause rejection, and recent work pointed their role in mediating tolerance in transplantation. The unique T-cell receptor (TCR) expressed on the surface of each T cell determines the antigen specificity of the cell and can be the specific fingerprint for identifying and monitoring. Next-generation sequencing (NGS) techniques provide powerful tools for deep and high-throughput TCR profiling, and facilitate to depict the entire T cell repertoire profile and trace antigen-specific T cells in circulation and local tissues. Tailing T cell transcriptomes and TCR sequences at the single cell level provides a full landscape of alloreactive T-cell clones development and biofunction in alloresponse. Here, we review the recent advances in TCR sequencing techniques and computational tools, as well as the recent discovery in overall TCR profile and antigen-specific T cells tracking in transplantation. We further discuss the challenges and potential of using TCR sequencing-based assays to profile alloreactive TCR repertoire as the fingerprint for immune monitoring and prediction of rejection and tolerance.

Keywords: alloreactive, T-cell receptor repertoire, transplant, biomarker, high-throughput sequencing

INTRODUCTION

T cells recognize antigens through their TCRs binding to antigen-presenting cells (APCs) surface peptide-major histocompatibility complex (pMHC) (1). The binding will result in changes in the CD3 molecule complex and initiate downstream signaling pathways, which are called TCR triggering. Subsequently, cells with foreign or self-mutated pMHC will be distinguished and eliminated by T cells (2, 3).

The T-cell repertoire covering the enormous foreign and self-mutated antigens is achieved *via* highly polymorphic TCRs (4, 5). As the determining factor of antigen-specificity and the potential of being used as the molecular identifiers of T cells, TCRs receive special attention in many fields of diseases, such as infectious diseases, autoimmune diseases, and malignant tumors (5–7). In immune processes, TCR repertoire analysis provides information on the T cells dynamics with respect to diversity and clonality. The characterization of TCR repertoires in transplantation can depict the T-cell dynamics at multiple timepoints, and recipient or donor antigen-specific TCR repertoires can be used for fingerprint recognition in tracing the alloresponse and assisting with diagnosis and treatment.

T CELLS IN TRANSPLANTATION

During the T cell selection process in the thymus, the affinity between TCRs and self-pMHC molecules play a central role. Only those T cells with appropriate binding affinity with self-MHC and do not recognize self-antigen will survive in the positive and negative selection. This is the basis of T cell distinguishing foreign antigens from self-antigens (8, 9).

Following the upregulation of S1P1, T_N (naïve T cell) cells enter the periphery *via* lymphatics or blood vessels (10), and express a series of typical molecules, including CD62L and CCR7, which are necessary for the subsequent trafficking of T_N cells between the secondary lymphoid organs (11, 12). After being exposed to antigens, T_N cells have no immediate effector functions. The activation and proliferation of T_N cells depend on signals. The first signal is received through TCR engagement with pMHC complexes and the second signal is relayed through costimulatory receptors, of which CD28 is dominant. After the signals cross the activation threshold, T_N cells are activated, and will initiate clonal expansion and effector differentiation to acquire capacity to eliminate target cells by recognizing the alloantigen. A small portion of the T cells can differentiate into long-lived memory cells. When encountering the same antigen again, memory T cells can be activated with limited co-stimulation signal and respond to lower doses of antigen compared with T_N cells (13, 14). Actually, the memory T-cell repertoires in adult human contain high frequencies of pre-existent alloreactive memory T cells that are able to infiltrate the graft rapidly and cause rejection through alloresponse (14–16). These alloreactive memory T cells, mainly CD8 T cells (17), can locate within the lymph nodes (central memory T cell, T_{CM}), peripheral non-lymphoid tissues (resident memory T cell, T_{RM}), or periphery (effector memory T cell, T_{EM}) and stay resting until they encounter the same antigen again post-transplantation. Through quantitative analysis of alloresponse *in vitro*, up to 10% of peripheral T cells were considered potentially alloreactive (18, 19).

There are many mechanisms for the generation of pre-existing alloreactive memory T cells before transplantation. Humans exposed to alloantigens through previous transplantation, blood transfusion, or pregnancy may produce alloantigen-specific memory T cells (20–22). Without contact with allogeneic MHC molecules, the exposure to commensal bacteria or environmental antigens is also probably to induce potent heterologous immunity, which is one way for the generation of alloreactive memory T cells (23, 24). Many studies have identified that alloreactive T-cell clones can also stem from other immune events (25, 26), such as dozens of virus-specific (CMV, EBV, Flu, HIV, Zika Virus, SARS-CoV-2) memory T cells that show cross-reactivity to allogeneic pMHC complexes (27–32). Thereby, these memory T cells can also pre-exist in the host even if they have not previously encountered donor-derived antigens.

A series of studies have indicated that both naïve and memory alloreactive T cells are the mediators of the alloreactive immune response in transplantation (33, 34). They make contribution to both acute and chronic rejection episodes depending on the pathway recognizing donor antigens (35, 36). Host T cells

recognizing processed donor allogeneic peptides presented by host MHC is indirect allorecognition (37). Allogeneic T cells that recognize nonself MHC molecules from the same species are also responsible for the alloresponse in allotransplantation, called direct T-cell allorecognition (38). In some settings, intact donor MHC can be transferred to the surface of recipient APCs, activation of recipient allogeneic T cell by the engagement of recipient TCRs with this donor-derived MHC on recipient APC is called semidirect pathway (39, 40). Direct pathway responses are considered strong but only last a short time and likely mediate the acute rejection, whereas indirect pathway responses are viewed as be more long-term and responsible for mediating chronic rejection. These pathways may be involved in mediating allograft rejection at the same time or at different times. During the process of transplantation, both alloreactive naïve T cells and pre-existing memory T cells are exposed to high and long-lasting alloantigen loads to mediate rejection through direct and indirect pathways. Indirect pathway-mediated rejection largely depends on the T_N repertoire, while direct pathway-mediated rejection involves both naïve and memory T cells (41). Oberbarnscheidt et al. reported that T_{EM} played an important role in immune surveillance of grafts and had no need to return to secondary lymphoid tissues to differentiate for effector functions in mouse model (42). In humans, through measuring peripheral T cells from healthy donors based on flow-cytometry, Macedo and colleagues reported the proliferation rate of $CD4^+$ and $CD8^+$ T_N cells under the stimulation from allogeneic cells was similar with their memory counterparts *in vitro* (43). Similar findings were also reported in mouse model for direct allorecognition by naïve and memory T cells (44, 45).

Although the contribution is small, alloreactive T cells can also derive from dual TCR T cells with two distinct TCR α chains that give one T cell two distinct antigen-specificities and double the chance of antigen recognition (46, 47). In studies of mice, it has been shown that dual TCR T cells have a high frequency of alloresponse (48). In acute graft versus-host disease (GVHD) patients, the frequency of dual receptor T cells is 5.3 times higher than that in healthy controls (49).

To suppress rejection or to induce tolerance, treatment is usually targeted at both naïve and memory T cells. Long-term administration of immunosuppressive drugs after transplantation is the most common therapeutic option for depleting naïve and memory T cells or preventing their full activation for acute cellular rejection (ACR). A similar effect can be induced by alloreactive T-cell exhaustion. Long-term or large loads of foreign antigen exposure to T cells may lead to antigen-specific T-cell exhaustion (50). During the first 6 to 12 months post-transplantation, the faltering demand for immunosuppressive therapy as well as the decline in the incidence of ACR coincided with the increase in the frequency of exhausted T cells (T_{EXH}) (51). Fribourgt et al. demonstrated that T_{EXH} development was correlated with better clinical outcomes (52). Another way to induce tolerance is through the adoptive transfer of regulatory T cells (Tregs). Tregs are a suppressive subset of T cells and can inhibit the function of conventional T cells and other immune cells (53), and have been well demonstrated to induce tolerance in

various types of transplantations (54–57). For example, in solid organ transplantation clinical trials, polyclonal Tregs had been proved to be safe and effective in alloresponse repression. Antigen-specific Treg therapies, such as Treg engineered with antigen-specific TCRs (TCR-Tregs) and chimeric antigen receptor (CAR)-modified Tregs (CAR-Tregs), further overcame the shortage of a limited number of ex vivo Tregs expansions by performing the suppressive function in a more effective and antigen-specific way on alloreactive T cells (58–60).

TCR IN ALLORESPONSE

The specificity of T cells is determined by their TCRs (4, 61). The TCR consists of two distinct chains. For human beings, the overwhelming majority (95%) of circulating T cells express TCRs composed of an α chain and β chain. And there is a small subset, the TCR of which is composed of a γ chain and δ chain (62, 63) (**Figure 1A**). $\alpha\beta$ T cells are the central mediators of the adaptive immunity with great diversity, recognizing antigens presented related to MHC Class I and II proteins. To cover a wide range of potential pathogens and harmful substances, billions of unique TCR molecules need to be generated *in vivo*, and this extraordinary heterogeneity of TCRs is achieved through their variable region. Both chains of TCRs include a highly variable complementarity determining region 3 (CDR3), which are the binding sites with MHC peptide and mediate TCR engagement (64). The rearrangement of variable (V), joining (J), and diversity (D) gene segments and the random insertion or deletion of nucleotides at the junction of gene segments leads to generation of variable exons, that is the major factor contributing to the diversity of TCR sequences (65, 66) (**Figure 1B**). The theoretically estimated number of possible gene combinations generated during the lifespan of human beings is 10^{15} to 10^{20} (67).

V(D)J recombination influenced by both genetic and epigenetic factors leads to the formation of pre-selection TCR repertoire (68, 69). During the thymus selection, the TCR repertoire will be selected by self-MHC ligand and antigen. Thymic selection will purge the majority of clonotypes and only a few T cells that are granted access to the periphery to make up the naïve TCR repertoire. T cells selected by self-MHC, and clones bearing TCRs within additional affinity to allo-MHC will not be removed during this process. Thus, the process initially shapes a naïve T cell repertoire containing T cells that have the potential of interacting with allo-antigen/MHC (**Figure 1C**).

Moreover, recent experimental evidence also supports that each T cell has the potential to interact productively with more than one pMHC complex (70). The cross-reactivity of TCRs on specificity not only provides potential immune coverage but also increases the risk for transplant rejection. The clones from antigen-experienced TCR repertoire could also be involved in alloresponse (**Figure 1C**). Distinct pMHC complexes could have a similar surface conformation due to the shared conformation between MHC molecules and peptides. Therefore, allogeneic

pMHC could be recognized by TCRs through imitating the unique features of peptides presented by self-MHC (71). The overlap between alloreactive clones and known public virus-reactive clones has been proved by the shared TCR sequences of them. And crystal structures have shown that due to the plasticity of the CDR loops, TCR could adapt to structurally diverse pMHC ligand by small conformational changes or rearrangements of its central CDR loops, this recognition can be driven by unique features of both the peptides and allo-MHC molecules (64, 72, 73) (**Figure 1D**). Recent *in vivo* finding dictates that the self-peptides bound to a handful of allogeneic MHC-peptide complexes account for a large proportion of the alloresponse, and the complex of self-peptide and allo-MHC molecule plays a critical role in transplant tolerance induction (74).

Many examples of TCR bias have been observed in various diseases. Based on the CDR3 sequences, the T cell clones within different tissues, timepoints, individuals, and even species are able to be traced and quantified (75, 76). The analysis of total CDR3 lengths and distribution has been adopted to measure the degree of clonality and diversity of T cells during the immune response. Certain clonal expansion and reduction also exhibit T cell-mediated immune responses caused by specific antigens (77). In addition, these sequences can be identified by matching with a reference antigen-specific TCR repertoire (78). The unique TCR repertoires are used as the fingerprints to monitor immune status and predict response.

Through one-way mixed lymphocyte reaction (MLR) using responder and stimulator cells from different individuals, Emerson et al. first characterized the alloreactive TCR repertoire in healthy adults (79). However, there is no unique CDR3 length or gene usage in alloreactive T cell populations compared with other non-alloreactive clones, which means that there may not be a unique feature of the alloreactive TCR repertoire. Although there was a small amount of highly abundant clones in the alloreactive clones, likely memory clones, the frequencies of most alloreactive clones in circulation were at naïve levels, which further supports the high diversity of alloreactive TCR repertoire. Indeed, the T_N repertoire does have a far higher diversity compared to the memory counterparts (80, 81), as the repertoires of memory T cells have contracted due to the previous clonal expansion, while the naïve pool has not been exposed to antigens and are less affected. Therefore, it is understandable that the repertoire of unprimed T_N cells has better coverage of allogeneic pMHC. Moreover, another *in vitro* experiment showed that the alloreactive TCR repertoires in the same recipient were disparate when the donor antigens were from two individuals (19, 82).

Unlike some pathogen antigen-specific TCR repertoire which has a preferential usage of V and J gene segments and dominant CDR3 length (83), the lack of uniform feature and the diversity of the alloreactive CDR3 hinder the characterization of alloreactive TCR repertoire. Fortunately, TCR sequencing combined with *in vitro* MLR that proved to be reliable and sensitive opens up a new way for annotating alloreactive TCR sequences and capturing alloresponse (79).




FIGURE 1 | (A) $\alpha\beta$ TCR consists of α and β chain, $\gamma\delta$ TCR is composed of γ and δ chain. Each subunit has constant regions and variable regions that are site of antigen recognition. (B) V, D, and J gene segments are progressively rearranged to form the final DNA sequence. This variability is further increased by deletion and insertion of nucleotides at the junction sites. After transcription, the sequence between the recombined V(D)J regions and the gene encoding the C region will be spliced out. V gene encodes CDR1 and CDR2, whereas junction of the V(D)J genes encodes CDR3. (C) Pre-selection TCR repertoire is stochastic and diverse. Thymic selection purges most of clones and shapes the naive TCR repertoire which contains alloreactive clones. Antigen exposure leads to clonal expansion of antigen-specific T-cell clones that may also have the potential of the cross-recognition with allo-antigen/MHC. (D) Allo-MHC could be recognized by host-TCR through imitating the unique features of host-pMHC complex.

HIGH-THROUGHPUT TECHNOLOGY REVOLUTIONIZED METHODS FOR MEASURING ALLORESPONSE

To characterize antigen-specific T cells in human tumors, infectious diseases, and transplantation, various low-throughput methods have been proposed and developed (84).

However, these low-throughput methods screen a limited number of T or B cells against a few antigens at one time (85).

Monoclonal antibodies against the $V\beta$ chain of TCRs to describe the T-cell repertoires at the protein level, which enabled qualitative and quantitative determination. However, limited to the types of antibodies with specific recognition site, this method offers less coverage and it does not reveal any

information on CDR3 diversity (86, 87). The distribution of CDR3 sequence length in the entire T-cell repertoire was first exhibited through CDR3 spectratyping (88). And Sanger sequencing was applied to measure the TCR repertoire at the gene level and describe it in more detail (89, 90). But it was not enough to determine the diversity of the entire TCR repertoire, because only a few high sequences could be captured to construct the library (91).

NGS technology has made significant progress in the field of TCR analysis (92, 93), which introduced high-throughput, and ultra-sensitive techniques to provide detailed information of the TCR arrangement including V, D and J segments and the full sequence of CDR3 (94, 95). This high-resolution method is capable of capturing clones at extremely low frequencies. It enables to deeply profile the TCR repertoire and fully reveals the clonotype composition of T cells (96). NGS technology are able to not only monitor the TCR repertoire of a single individual on serial samples over time, but also achieve a quantitative comparison of the repertoires between two or more individuals (97). NGS improves sensitivity, reduces sequencing costs, and allows for monitoring of the immune response in large queues and at continuous timepoints.

Current high-throughput sequencing techniques that use genomic DNA (gDNA) or RNA as starting materials to construct a TCR repertoire have advantages and limitations, and the optimal choice depends on the study of interest (**Figure 2A**). Approaches based on gDNA employ multiplex amplification, a set of forward PCR primers complementary to all possible V segments and a set of reverse primers complementary to the J segments (98, 99). gDNA is stable, and there is only one copy of single gDNA in each cell to encode TCR. Therefore, gDNA-based methods allow for directly quantifying the frequencies of alloreactive clones and avoid the discrepancy in transcription levels introduced by the different activation states. In addition, initiating with gDNA skips the process of reverse transcription, that also reduces errors caused in cDNA synthesis (98). But allelic exclusion would be not considered, leading to the result that the diversity will be overestimated. And the multiplex PCR would add unavoidable amplification bias, that will interfere with the quantification of TCR sequence in the original gDNA and lead to the distortion of frequencies. RNA-based methods lean on 5' rapid amplification of cDNA ends (RACE), which requires a fewer rounds of PCR to reduce amplification bias (98). Unique molecular identifiers (UIDs) strategy can also be applied to further reduce PCR error to achieve absolutely quantify (100, 101). Employing RNA as starting materials potentially enables to obtain the complete V and J gene sequences and provides information at nucleotide level. But RNA-based methods tend to reflect the level of gene transcription more than the absolute original cell count, and it requires high amount and quality of the starting material.

When extracting gDNA or RNA to derive informative repertoires from solid tissues or body liquids with T cells, only a small part of the sequence reads come from T cells and could correspond to TCR, so even a very high sequencing depth will cause a loss of information. Furthermore, the comparison of TCRs in different T cell subpopulations would reveal important insights into the T cell subset function, that are occluded in bulk TCR analysis. FACS sorting combined with deep TCR sequencing

could enrich T cells from tissue samples or directly obtain certain T cell subgroups to facilitate more comprehensive and detailed TCR analysis (102–104). According to specific surface markers or dye, FACS sorting can also be applied to isolate alloreactive T cell subsets with cytotoxic function and particular cytokine production patterns (**Figure 2B**) (82, 105, 106).


The recent development of single-cell sequencing allows the transcriptomes of more than tens of thousands of cells to be processed simultaneously (107, 108). The combination of TCR sequencing and gene expression provides new insights into role of alloreactive T cells in alloresponse (109, 110). The total transcriptome information of a single cell can be collected and further be matched with the TCR sequence by the identical barcode sequence. In this way, each alloreactive T-cell clone can be traced through TCR and the function and development can be analyzed by gene-expression within cell (111, 112) (**Figure 2C**). Approaches based on single-cell could also obtain pairing information of the α chain and β chain to increase the ability to discover heterogeneity (102, 113, 114).

Now these approaches are widely used for characterizing the TCRs pairing and clonality and have been employed to the analysis of T-cell repertoire in various physiological or pathological states (115), including the monitoring of alloresponse by profiling total TCR repertoire dynamics and antigen-specific T cell repertoire. TCR sequencing at bulk and single-cell level allows for the more in-depth investigation of the alloreactive T cell repertoire and potential translation to clinically applicable tools.

IMMUNOLOGICAL CHARACTERISTICS OF THE OVERALL TCR REPERTOIRE IN TRANSPLANTATION

Following transplantation, pre-existing alloreactive T cells are activated and clonal expanded by alloantigen from the graft. The accumulation of alloreactive T cells were observed in graft rejection (116, 117), which causes the recipient overall TCR repertoire skewed by predominant clones arising from alloresponse, and the deletion or absence of alloreactive T cells was proved in recipients within long-term graft acceptance (50, 74, 118). Therefore, information about the overall TCR repertoire would reveal the immune states of recipients after transplantation.

The changes of the diversity in the overall TCR repertoire of recipients with different clinical outcomes have been researched to reflect the T cells dynamics after solid organ transplantation (119, 120). In kidney transplantation clinical trial studies, the TCR repertoires of rejected patients were skewed related to the level of transplant lesions classified by Banff classification, while the TCR repertoires of operational tolerance patients exhibited less skewed and maintained diversity (121, 122). However, these studies only characterized the most abundant clones owing to the application of low-throughput techniques, while ignoring most of the subdominant and low-frequency ones. Methods based on the high-throughput bulk TCR sequencing provide higher sequencing coverage results



to depict the entire T-cell repertoire, including TCR repertoire structure, turnover, clonality, and diversity at time points before and after transplantation.

By using the high-throughput bulk TCR sequencing method, research revealed combined kidney and bone marrow transplantation (CKBMT) recipients have a higher repertoire turnover rate than non-rejective traditional transplant recipients, which is consistent with the more effective donor-reactive T cells depletion treatment under CKBMT conditions (123). The diversity of CD4 T cells in CKBMT rejected recipients exhibited decreased tendencies after transplantation, while the diversity in tolerant recipients returned to the pre-transplantation levels. There was no difference in the diversity of CD8 T-cell repertoires was observed between groups.

In a kidney transplantation study, Alachkar et al. observed the TCR repertoire of transplant patients was relatively

restricted compared with the healthy donor, which may be related to their pathology. A rapid turnover of the TCR repertoire in circulation during T cell-mediated rejection (TCMR) was reported (124), which was absent in non-TCMR patients. Additionally, the TCR repertoire of peripheral blood was highly related to that of graft during rejection suggests that noninvasive blood-derived TCR analysis has the potential to detect renal transplant rejection.

In liver transplantation (LTx), the diversity of TCR sequences was significantly decreased when acute allograft rejection occurred compared to the patients with stable allograft liver function and healthy controls, which was similar to renal transplantation (125). TCR repertoire of patients undergoing rejection appeared to have short N-additions, which may imply the recombination diversity of CDR3 during rejection. For most recipients, the diversity of TCR repertoires changed after transplantation. The overall clonality in

CD8 T cells was also higher than that in CD4 T cells post-LTx, which was consistent with pre-LTx (105).

During GVHD, TCR deep sequencing analysis shows highly skewed T-cell repertoires of tissues, which matches the oligoclonal expansion pattern in previous studies about TCRs (126, 127). These T cells distribute differently from tissue to tissue in a patient, and the T cells infiltrated within solid tissues are highly individual-specific. Some studies indicated that the frequencies of clonotype from tissue and peripheral blood were not related (128, 129), but Beck et al. indicated that some clonotypes were shared (130). In fact, the TCR repertoire of peripheral blood is far more diverse and mixed than local organs, and the tissue-infiltrating T cells in circulation with low frequencies and in target tissue with high frequencies could reflect the clonal expansion in target tissues during GVHD.

In summary, the dynamics of overall TCR repertoires were related to the immune state post-transplantation, which possesses the potential to be a reference for clinical immunosuppression strategies. Additionally, the overall TCR repertoire profiling provides information about the immune status of the recipient on the waiting list before transplantation, which might be an indicator of the risk of rejection or GVHD after transplantation, but this needs further investigations. In kidney transplantation, the dominant T cell clones in the graft during TCMR could be detected in the blood and biopsy earlier, which indicates that the clonal expansion of alloreactive T cells may be much earlier than the occurrence of TCMR, and possesses the potential of being used as a biomarker for early diagnose of TCMR (124). And the entire TCR repertoires of patients with different clinic outcomes differ in terms of diversity index, physical and chemical properties, and turnover rate. These changes of TCR repertoires before or during TCMR indicate the potential of TCR repertoire to predict the rejection as a biomarker. However, the entire TCR repertoire analysis only provides information for the T-cell repertoire and leaves the antigen-specific T-cell clones profiling concealed.

MONITORING THE T CELL-MEDIATED ANTIGEN-SPECIFIC ALLORESPONSE BY TCR SEQUENCING IN TRANSPLANTATION

Through tracking unique TCRs in tissues and body fluids, the expansion or reduction of antigen-specific T-cell clones can be quantified (131, 132). In the context of transplantation, tracking and monitoring graft versus host (GVH) and host versus graft (HVG) alloreactive T cells before and after transplantation in the peripheral blood, bone marrow (BM), and graft allows for a comprehensive view of the T-cell mediated alloresponse. And immunodominant clonotypes in target tissue have also aroused interest as surrogate markers for the T-cell mediated immune response in transplantation (130). Nevertheless, antigen specificity of alloreactive T-cell clones in transplantation varies from patient to patient and even from tissue to tissue, which


brings great difficulty to determining the individualized alloresponse for each subject (126, 133).

MLR using donor and recipient cells could be applied to identify the alloreactive clones of each patient after transplantation. In renal transplantation, Dziubianau et al. used donor T cell-depleted peripheral blood mononuclear cell (PBMC) as stimulators in a short-term MLR with T cells in the allograft and urine post-transplantation for assessing recipient alloantigen-specific T cells in these samples (96). They reported the identification of donor-reactive clones within allografts and urine was associated with ACR. However, the frequency of these donor-reactive T-cell clones in these original samples and if it is related to ACR degree were not reported in this study.

To evaluate the deletion or accumulation of alloreactive T cells post-transplantation, an antigen-specific TCR repertoire can be constructed by carboxyfluorescein diacetate succinimidyl ester (CFSE) MLR combined with TCR-seq to quantify the frequency of alloreactive T cells. Instead of selecting alloantigen-specific T-cell clones directly in post-transplant samples as the former study, this approach obtains the alloreactive library of TCRs with pre-transplant samples MLR and monitors alloresponse prospectively. Covalently binding to amines in cells, the CFSE dye in one cell will divide in half when the cell divides into two, so the fluorescence intensity of the daughter cell is half of the original parent cell. Based on the flow cytometric analysis of MLR cultures, the cells that proliferate in response to allostimulation can be sorted.

Bettens and colleagues obtained the alloreactive TCR repertoire through a similar one-way MLR strategy and took bystander expansion during MLR into consideration (82). They set multiple pairs of responder and stimulator cells from healthy donors with various HLA combinations to perform MLR cultures to evaluate the T cell alloresponse in human. After 13 days of MLR, the responder cells were stimulated overnight by 'PHA blasts', which was the autologous PBMC without irradiation and activated with PHA, and then those responder T cells exhibited activated phenotype in the second step of MLR with these autologous cells were subtracted from the allogeneic T cell pool as the bystander component. After this two-step MLR, the CD8⁺CD137⁺ subpopulation was purified and sequenced as alloreactive activated cytotoxic CD8⁺ responder T cells (Figure 3A). In this study, either one responder cell stimulated with two individual HLA identical healthy donor stimulator cells, or two individual responder cells from two donors stimulated with one stimulator cell, resulted in disparate alloreactive T-cell clones. This study highlighted the necessity of personalized alloreactive T-cell library construction.

Using a similar strategy, Zuber and his colleagues constructed both HVG and GVH repertoires and deleted the bystander clones by excluding 4-fold less proliferative clones in MLR compared with the original responder cell sample clone frequency. By these HVG and GVH libraries, they investigated the recipient T_{RM} replacement in graft after intestinal transplantation (ITx) and confirmed that the rate of donor T_{RM} turnover in the graft is influenced by two-way alloreactivity (117). GVH reactive clones that were enriched and persisted for long time in the graft were correlated with reduced risk of rejection. In contrast, rejection occurred when HVG reactive



clones dominated in the graft and accelerated the T_{RM} turnover, and these clones acquired a kind of steady tissue-resident phenotype. Moreover, the expanded GVH reactive T cells protecting the allograft against rejection have been shown by profiling GVH clones transcriptomes using single-cell RNA sequencing combined with TCR sequencing to demonstrate a cytotoxic effector phenotype (116). They attacked recipient hematopoietic cells and make space in the BM, resulting in the long-term engraftment of donor-derived hematopoietic stem and progenitor cells (HSPCs) to the BM and finally inducing central tolerance which led to the durable chimera (134). By identifying HVG and GVH clones within the allograft, PBMC and BM, the mechanism of tolerance induction through GVH T cells was well demonstrated.

Based on the same method, Morris et al. detected fingerprints of the alloreactive T cell in CKBMT using pre-transplant materials (123). Through deep-sequencing of proliferating recipient CD4 and CD8 T cells after 6 days of MLR with donor lymphocytes as stimulators, the author obtained a mappable HVG reactive T-cell repertoire library and track these HVG clones as alloreactive T-cell clones after transplantation (**Figure 3B**). The result suggested that the dominant donor-reactive clones in *in vitro* MLR culture were

most likely to expand post-transplant. By evaluating expansion or deletion of clones, reduction of circulating HVG reactive T-cell clones was observed in tolerant patients, while HVG clones were observed in nontolerant recipients, which suggested that elimination of HVG reactive T-cell clones appeared to be a mechanism of allograft acceptance in CKBMT patients. In contrast, kidney transplant recipients receiving conventional immunosuppression showed a persistent proliferation of HVG reactive T-cell clones in circulation following transplant. Similar results were observed in intestinal transplantation. The number of donor-reactive TCRs within the circulation of intestinal allograft recipients after transplantation increased (117). The successful identification of relevant donor-reactive clones following transplantation by pre-transplant MLR indicated that this method is reliable in identifying alloreactive T cells.

Unlike the expansion of circulating HVG reactive T-cell clones of conventional kidney allograft recipients, even if there is a lack of demonstrable tolerance, a decrease in circulating HVG reactive TCRs could be observed in LTx recipients (118). This may be related to the distinct distribution of T cells between liver-graft and circulation. This distinct distribution of T cell pool

between liver-graft and blood was demonstrated by Mederacke et al. They used a time-saving MLR method by incubating recipient T cells sample for 24 hours with irradiated donor splenocytes as stimulators prior to transplantation, and subsequently sorted and sequenced the CD154 positive cell as alloreactive effector T cells (Teffs) (105) to construct the HVG TCR library (135, 136) (Figure 3C). Then they tracked HVG reactive T-cell clones at multiple time points in blood samples, and reidentified those clones in the liver biopsies. They found that TCR repertoires in circulation were distinct from that in liver-graft. But they also found the HVG clones were more correlated between allo-graft and blood in ACR patients compared with patients without ACR. They also tracked HVG Tregs, as glycoprotein A repetitions predominant (GARP) positive cell in MLR, within the peripheral blood and liver allograft in four patients with no suspected rejection, and found donor-reactive Tregs preferred to accumulate in the liver of these patients, which may be related to their function to suppress immune responses and prevent rejection (60).

In the field of transplantation, the strategies to accurately predict and recognize the rejection or tolerance are still lacking. Alloreactive T cells are considered to take responsibility for the occurrence of rejection and the failure to induce tolerance. Using an HVG or GVH TCR repertoire to identify alloreactive T cell clones provides new insights into T cell mediated allo-response and illustrates the mechanism of rejection or tolerance in transplantation, and it holds potentials for clinical usage in the future. Donor-reactive clones accumulating in the body fluid might be a biomarker for predicting rejection or GVHD in certain types of transplantation, so tracking these clones could instruct the personalized immunosuppression in clinic. The alloreactive TCR repertoire is prospectively and non-invasive in the prediction and diagnosis of rejection, and has less inter-observer bias compared to histological sectioning and staining. The combination of TCR sequencing with FACS sorting or single-cell sequence can enhance posttransplant immune monitoring and immunophenotyping of alloreactive T cells in a clinical setting (Figures 2B, C). Additionally, some infections after solid organ transplantation could cause similar tissue damage like that in rejection and bring diagnostic challenges, so tracking the arising of donor-reactive clones referring to an alloreactive TCR repertoire can contribute to the diagnosis of posttransplant complications. Moreover, deletion of alloreactive TCRs in the blood was proved to be related to tolerance induction in certain types of transplantation, which could serve as a biomarker for the immunosuppression withdraw. The alloreactive TCR repertoire may open a new way of evaluating the establishment of immune tolerance or distinguishing tolerant patients from non-tolerant patients.

But there are challenges in translating it into clinic. The construction of alloreactive TCR repertoire is limited by the pre-transplant material and intensity of MLR. Pre-transplant MLR for alloreactive repertoire requires both donor and recipient cells before transplantation, an insufficient number of pre-transplant cells or too weak MLR may result in too few identified donor responsive clones. But it still possesses a potential of clinical application, since 10-20ml of blood can provide millions of T cells as stimulators or responders, and

tens of thousands of alloreactive clones can be obtained using donor and recipient pretransplant peripheral blood samples as starting materials. For the analysis of samples with low cell number, alloreactive T cells from MLR could be expanded *in vitro* by an unbiased polyclonal expansion method to get enough cells for TCR sequencing to construct the alloreactive TCR library. And NGS is able to analyze alloreactive clones at extremely low frequencies. Additionally, several factors should be taken into consideration in alloreactive TCR library construction. Differences in allogeneic MLR coculture duration can result in different size and diversity of the alloreactive T-cell repertoire, since the alloresponse mediated by direct recognition pathway or indirect recognition pathway often occur at different periods after transplantation *in vivo*, and the overlap of TCR repertoires in these two pathways mediating the alloresponse is largely unknown in this field. And identifying alloreactive T cells by early activation markers shortens the time of MLR and can obtain enough donor-reactive T-cell clones compared with CFSE-based MLR (105, 118), but the expanded bystander T-cell clones should be removed from the alloreactive TCR library (82, 106). Also, the tracking result is limited by the post-transplant sample size, some patients under pathological conditions after transplantation, such as lymphopenia caused by GVHD or certain virus infection, may result in reduced T cell number in samples, which would cause failure in antigen-specific T cell clone tracking. Lastly, the different distribution of T-cell clones between tissues and circulation should be considered to avoid a skewed TCR repertoire in the starting T-cell repertoire, to better serve the research purpose by targeting as much as possible antigen-specific T-cell clones in constructed alloantigen-specific TCR repertoire.

THE POTENTIAL OF USING COMPUTATIONAL TOOLS TO CHARACTERIZE THE TCR REPERTOIRE

Although the biochemical and molecular basis of TCR recognition of allogeneic peptide/MHC is becoming clearer, the ignorance about specificities of alloreactive T cells still limits the biological insights into alloresponse. Existing computational tools for alloreactive TCR repertoire annotation allow both matching against databases of known antigen specificities and clustering of TCR sequences through algorithms (109). With these public tools, annotating TCR repertoire data in alloresponse and integrating alloantigen-specific clones can be more efficient.

The international Immunogenetics Information System (IMGT) includes a database that providing reference sequences for individual gene of T-cell receptors, and annotations of known gene segments (137). It allows user to submit nucleotide sequences to identify the V, D and J genes and alleles and characterize clonotypes. To share data and annotate TCR repertoires with predicted antigen specificities, a series of databases across studies were established (138, 139) (Table 1). In McPAS-TCR, TCR

TABLE 1 | Summary of TCR databases.

	Function	Species	Available information	Source
IMGT (140)	A system that bridge biological and computational spheres in bioinformatics	Human, rat, goat, monkey, dog, rabbit, pig, cat, sheep and frog	Locus, genes, alleles, proteins, probes, structures, clinical entities	http://www.imgt.org/IMGTrepertoire/
McPAS-TCR (139)	A manually curated catalogue of pathology-associated TCRs	Humans and mice	Epitope, disease condition, T cell type, tissue, source organism, MHC restriction, assay type	http://friedmanlab.weizmann.ac.il/McPAS-TCR/
VDJdb (138, 141)	A database of TCRs with known antigen specificity	Humans, mice and monkeys	Epitope, antigen, MHC, HLA type, assay types and sequencing methods	https://vdjdb.cdr3.net/
VDJserver (142)	A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements	Human and mice	Gene usage, diversity, length, amino acid utilization, and physicochemical properties of CDR3 patterns	https://vdjserver.org/
iReceptor (78)	A platform for querying, analyzing and downloading antibody/B-cell and T-cell receptor repertoire from multiple independent repositories	Human and mus musculus	Study types, organisms, diagnoses, tissues, PCR targets and target substrates	http://ireceptor.irmacs.sfu.ca/

sequences associated with various antigens were manually arranged according to published literature (139). And VDJdb collects published T-cell specificity assays and lists TCR sequences with experimentally verified epitope specificities as well as their MHC restrictions (138). Some databases such as VDJServer and iReceptor, places extra emphasis on sharing data on adaptive immune receptor repertoire (AIRR), and provides online AIRR-seq data of interest for conjoint analysis and data mining (78, 142). The AIRR Community was formed to solve problems in AIRR sequencing studies (143). To meet the need for queries across repositories, standard procedures for AIRR-seq data acquisition, storage, submission, annotation, and sharing are established and a common file format is proposed, which will create a unified environment of data analysis for individual researchers.

The TCRs of T cells may share antigen specificity and recognize the same peptide-MHC ligands even if their amino acid or nucleotide sequence are different (144). TCR clustering tools cluster TCRs of similar specificity by algorithms related to the combination of different factor (**Table 2**). Dash et al. developed TCRdist based on the structural information on pMHC binding (145). This analytical tool can quantify the similarity of TCRs according to distance on the space and assign unknown TCRs to epitope-specific receptors repertoires. A distance score is computed by comparing all CDRs using a similarity-weighted Hamming distance. Although TCRdist is considered to be an effective high-clustering metric, the requirement for pairwise Smith–Waterman (SW) alignment on both the CDR3 sequences and the variable gene alleles limits the size of the TCR repertoire that can be clustered. GLIPH (grouping of lymphocyte interactions by paratope hotspots)

can retrieve and group similar TCRs of common specificity within an individual or across a group of donors through scoring based on multiple factors, including the motif, CDR3 length, shared HLA among contributors (148). This clustering algorithm can be used for the detection of antigen-specific TCRs and predicting the specificity of a new TCR, with no need of knowing the epitope. Those algorithms classify TCRs by calculating similarity, which is inefficient and strenuous to deal with large cohorts of TCR-seq samples. As an improved version, GLIPH2 greatly accelerates the analysis of TCR sequences with high clustering efficiency and accuracy (146). Apart from a series of scores for clustering, the fisher-exact test is introduced to filter given motifs for significance. In GLIPH2, a TCR sequence can be assigned to more than one cluster. iSMART allows comparison between CDR3s of different length and imposes a gap penalty. It also has high average purity for large clusters and fast speed for calculation. CDR3s will be first ordered the by length, and then compared in pairs (25). Geometric Isometrybased TCR Alignment Algorithm (GIANA) focuses on fast handling large-scale TCR datasets and increases efficiency while maintaining the same level of accuracy (147). These TCR clustering tools can divide large numbers of TCR sequences into groups with shared specificity and identify antigen-specific TCR groups according to the known TCR sequences in the groups (149).

A large set of TCR-antigen specificity data is required for understanding the structure and features of alloresponse due to the huge diversity of TCR sequences and pMHC. But the cells driving alloresponse may be small in number, and the alloreactive TCR repertoires in each small cohort may be drowned out in

TABLE 2 | Summary of methods for linking TCR-antigen specificity.

Method	Function	Approach	Source
TCRdist (145)	Matching TCR repertoire against a database of TCR sequences	Sequence similarity distance	https://tcrdist3.readthedocs.io/en/latest/index.html
GLIPH2 (146)	Clustering TCRs that are predicted to bind the same pMHC	K-mer enrichment-based detection of TCR motifs	http://50.255.35.37:8080/
iSMART (25)	Grouping similar TCRs into antigen-specific clusters	Pairwise local alignment on T cell receptor CDR3 sequences	https://github.com/s175573/DeepCAT/blob/master/iSMARTm.py
GIANA (147)	TCR clustering and multi-disease repertoire classification	Nearest neighbor search in the high-dimensional Euclidean space	https://github.com/s175573/GIANA

sequencing reads. Integrated online databases facilitate the accumulation and complex analysis of alloreactive TCR repertoire. Alloreactive TCR records can be submitted and arranged across species and tissue from multiple assays, including the CDR3 sequence, antigen, epitope, MHC and clinical presentation data, to help the identification and characterization of alloreactive TCRs and the epitopes they recognize. Algorithms help to further investigate specificities of alloreactive TCRs by calculating similarity. A deeper understanding of the alloreactive TCR repertoire will aid in the development of future immunomodulatory therapies in solid organ transplantation. And future studies in identifying allogeneic pMHC epitopes using these tools will enable the characterization of alloreactive TCR repertoires, which will provide further insights into the fundamental basis of alloresponse in biophysics and structure.

CONCLUSIONS

The development of NGS technology has brought improvements in TCR high-throughput and applications by making TCR repertoire analysis a basic tool for T-cell study in healthy physiological conditions and various pathological conditions. TCR sequencing of thousands to millions of cells shows the complexity and diversity not only of the whole TCR repertoire but also specific subset of T-cell clones in body liquids and various tissues. Linking the TCR repertoire with gene expression profiles led to further information, enabling to trace of specific T cells developmental fate and biofunction. The development of web databases and computational methods greatly expanded the available TCR information.

In the setting of transplantation, the dynamics of the overall TCR repertoires after transplantation are closely related to the immune status after transplantation. The diversity of repertoires and the rate of turnover is related to rejection or tolerance. The combination of MLR and TCR repertoire to track donor or recipient antigen specific T cells has been demonstrated as reproducible and sensitive. This method opens up a new path to monitor the T cell-mediated alloresponse after transplantation. Using the responders and stimulators in one-way MLR from the

donor and recipient cells materials before transplantation, a fingerprint of the HVG or GVH reactive T-cell clones during the alloresponse can be defined and tracked after transplantation. By tracking these clones, the clonal deletion or expansion of HVG and GVH reactive T cells reveals antigen-specific T-cell clonotypes are closely related to the immune status of the patients after transplantation and have a correlation with transplant outcome. Under certain circumstances, the clinical translation of TCR repertoires analysis in the peripheral blood would provide valuable information for treatment decisions. Hence, TCR repertoire analysis can noninvasively assist the diagnosis and treatment of transplant patients. In general, longitudinal monitoring of changes in the alloreactive clone size and overall TCR repertoire after transplantation can be used as a biomarker to predict tolerance or rejection in certain types of transplantation, eventually allowing individualization of immunosuppression in the clinic. And the characterization of alloreactive TCR repertoires and epitopes in the future will provide mechanistic insights into alloresponse.

AUTHOR CONTRIBUTIONS

GT wrote the manuscript and designed the figures. GL and ML edited and revised the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

Grants from Natural Science Foundation of China (grant number: 81901627 and U20A20360) will provide financial support for the open access publication fees of this paper.

ACKNOWLEDGMENTS

We thank the financial support of the National Natural Science Foundation of China (81901627 and U20A20360).

REFERENCES

- Jackson KJ, Kidd MJ, Wang Y, Collins AM. The Shape of the Lymphocyte Receptor Repertoire: Lessons From the B Cell Receptor. *Front Immunol* (2013) 4:263. doi: 10.3389/fimmu.2013.00263
- van der Merwe PA, Dushek O. Mechanisms for T Cell Receptor Triggering. *Nat Rev Immunol* (2011) 11:47–55. doi: 10.1038/nri2887
- Xu X, Li H, Xu C. Structural Understanding of T Cell Receptor Triggering. *Cell Mol Immunol* (2020) 17:193–202. doi: 10.1038/s41423-020-0367-1
- Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation. *Annu Rev Immunol* (2009) 27:591–619. doi: 10.1146/annurev.immunol.021908.132706
- Liu J, Zhang J. T-Cell Receptors Provide Potential Prognostic Signatures for Breast Cancer. *Cell Biol Int* (2021) 45:1220–30. doi: 10.1002/cbin.11562
- Sims JS, Grinshpun B, Feng Y, Ung TH, Neira JA, Samanamud JL, et al. Diversity and Divergence of the Glioma-Infiltrating T-Cell Receptor Repertoire. *Proc Natl Acad Sci USA* (2016) 113:E3529–37. doi: 10.1073/pnas.1601012113
- Schober K, Buchholz VR, Busch DH. TCR Repertoire Evolution During Maintenance of CMV-Specific T-Cell Populations. *Immunol Rev* (2018) 283:113–28. doi: 10.1111/imr.12654
- Ignatowicz L, Kappler J, Marrack P. The Repertoire of T Cells Shaped by a Single MHC/Peptide Ligand. *Cell* (1996) 84:521–9. doi: 10.1016/S0092-8674(00)81028-4
- Zúñiga-Pflücker JC. T-Cell Development Made Simple. *Nat Rev Immunol* (2004) 4:67–72. doi: 10.1038/nri1257
- Weinreich MA, Hogquist KA. Thymic Emigration: When and How T Cells Leave Home. *J Immunol* (2008) 181:2265–70. doi: 10.4049/jimmunol.181.4.2265
- Surh CD, Sprent J. Homeostasis of Naive and Memory T Cells. *Immunity* (2008) 29:848–62. doi: 10.1016/j.immuni.2008.11.002
- Gascoigne NR, Rybakina V, Acuto O, Brzostek J, Signal Strength TCR. And T Cell Development. *Annu Rev Cell Dev Biol* (2016) 32:327–48. doi: 10.1146/annurev-cellbio-111315-125324
- Pulko V, Davies JS, Martinez C, Lanteri MC, Busch MP, Diamond MS, et al. Human Memory T Cells With a Naive Phenotype Accumulate With Aging

- and Respond to Persistent Viruses. *Nat Immunol* (2016) 17:966–75. doi: 10.1038/ni.3483
14. Benichou G, Gonzalez B, Marino J, Ayasoufi K, Valujskikh A. Role of Memory T Cells in Allograft Rejection and Tolerance. *Front Immunol* (2017) 8:170. doi: 10.3389/fimmu.2017.00170
 15. Heeger PS, Greenspan NS, Kuhlenschmidt S, Dejelo C, Hricik DE, Schulak JA, et al. Pretransplant Frequency of Donor-Specific, IFN- γ -Producing Lymphocytes Is a Manifestation of Immunologic Memory and Correlates With the Risk of Posttransplant Rejection Episodes. *J Immunol (Baltimore Md.: 1950)* (1999) 163:2267–75.
 16. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL. Donor-Reactive CD8 Memory T Cells Infiltrate Cardiac Allografts Within 24-H Posttransplant in Naive Recipients. *Am J Transplant* (2008) 8:1652–61. doi: 10.1111/j.1600-6143.2008.02302.x
 17. Fischer M, Leyking S, Schafer M, Elsasser J, Janssen M, Mihm J, et al. Donor-Specific Alloreactive T Cells can be Quantified From Whole Blood, and may Predict Cellular Rejection After Renal Transplantation. *Eur J Immunol* (2017) 47:1220–31. doi: 10.1002/eji.201646826
 18. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the Frequency of Alloreactive T Cells *In Vivo*: New Answers to an Old Question. *J Immunol* (2001) 166:973–81. doi: 10.4049/jimmunol.166.2.973
 19. deWolf S, Grinshpun B, Savage T, Lau SP, Obradovic A, Shonts B, et al. Quantifying Size and Diversity of the Human T Cell Alloresponse. *JCI Insight* (2018) 3(15):e121256. doi: 10.1172/jci.insight.121256
 20. Verdijk RM, Kloosterman A, Pool J, van de Keur M, Naipal AM, van Halteren AG, et al. Pregnancy Induces Minor Histocompatibility Antigen-Specific Cytotoxic T Cells: Implications for Stem Cell Transplantation and Immunotherapy. *Blood* (2004) 103:1961–4. doi: 10.1182/blood-2003-05-1625
 21. Patel SR, Zimring JC. Transfusion-Induced Bone Marrow Transplant Rejection Due to Minor Histocompatibility Antigens. *Transfus Med Rev* (2013) 27:241–8. doi: 10.1016/j.tmr.2013.08.002
 22. Nadazdin O, Boskovic S, Murakami T, O'Connor DH, Wiseman RW, Karl JA, et al. Phenotype, Distribution and Alloreactive Properties of Memory T Cells From Cynomolgus Monkeys. *Am J Transplant* (2010) 10:1375–84. doi: 10.1111/j.1600-6143.2010.03119.x
 23. Akue AD, Lee JY, Jameson SC. Derivation and Maintenance of Virtual Memory CD8 T Cells. *J Immunol* (2012) 188:2516–23. doi: 10.4049/jimmunol.1102213
 24. Rudd BD, Venturi V, Smithey MJ, Way SS, Davenport MP, Nikolich-Zugich J. Diversity of the CD8+ T Cell Repertoire Elicited Against an Immunodominant Epitope Does Not Depend on the Context of Infection. *J Immunol* (2010) 184:2958–65. doi: 10.4049/jimmunol.0903493
 25. Zhang H, Liu L, Zhang J, Chen J, Ye J, Shukla S, et al. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers. *Clin Cancer Res* (2020) 26:1359–71. doi: 10.1158/1078-0432.CCR-19-3249
 26. Pogorelyy MV, Minervina AA, Shugay M, Chudakov DM, Lebedev YB, Mora T, et al. Detecting T Cell Receptors Involved in Immune Responses From Single Repertoire Snapshots. *PLoS Biol* (2019) 17:e3000314. doi: 10.1371/journal.pbio.3000314
 27. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. TCR Cross-Reactivity and Allorecognition: New Insights Into the Immunogenetics of Allorecognition. *Immunogenetics* (2012) 64:77–85. doi: 10.1007/s00251-011-0590-0
 28. Mifsud NA, Nguyen TH, Tait BD, Kotsimbos TC. Quantitative and Functional Diversity of Cross-Reactive EBV-Specific CD8+ T Cells in a Longitudinal Study Cohort of Lung Transplant Recipients. *Transplantation* (2010) 90:1439–49. doi: 10.1097/TP.0b013e3181ff4ff3
 29. Heutinck KM, Yong SL, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KA, et al. Virus-Specific CD8(+) T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected With CMV and/or EBV. *Am J Transplant* (2016) 16:1480–91. doi: 10.1111/ajt.13618
 30. Lim MQ, Kumaran EAP, Tan HC, Lye DC, Leo YS, Ooi EE, et al. Cross-Reactivity and Anti-Viral Function of Dengue Capsid and NS3-Specific Memory T Cells Toward Zika Virus. *Front Immunol* (2018) 9:2225. doi: 10.3389/fimmu.2018.02225
 31. Venturini S, Allicotti G, Zhao Y, Simon R, Burton DR, Pinilla C, et al. Identification of Peptides From Human Pathogens Able to Cross-Activate an HIV-1-Gag-Specific CD4+ T Cell Clone. *Eur J Immunol* (2006) 36:27–36. doi: 10.1002/eji.200425767
 32. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and Cross-Reactive SARS-Cov-2 T Cell Epitopes in Unexposed Humans. *Science (New York NY)* (2020) 370:89–94. doi: 10.1126/science.abd3871
 33. Felix NJ, Allen PM. Specificity of T-Cell Alloreactivity. *Nat Rev Immunol* (2007) 7:942–53. doi: 10.1038/nri2200
 34. Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-Versus-Host Disease. *J Immunol* (2005) 174:3051–8. doi: 10.4049/jimmunol.174.5.3051
 35. Brook MO, Wood KJ, Jones ND. The Impact of Memory T Cells on Rejection and the Induction of Tolerance. *Transplantation* (2006) 82:1–9. doi: 10.1097/01.tp.0000226082.17507.da
 36. Valujskikh A, Baldwin WM 3rd, Fairchild RL. Recent Progress and New Perspectives in Studying T Cell Responses to Allografts. *Am J Transplant* (2010) 10:1117–25. doi: 10.1111/j.1600-6143.2010.03087.x
 37. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB. The Indirect Pathway of Allorecognition. The Occurrence of Self-Restricted T Cell Recognition of Allo-MHC Peptides Early in Acute Renal Allograft Rejection and Its Inhibition by Conventional Immunosuppression. *Transplantation* (1995) 59:612–6. doi: 10.1097/00007890-199502270-00029
 38. Gould DS, Auchincloss H. Direct and Indirect Recognition: The Role of MHC Antigens in Graft Rejection. *Immunol Today* (1999) 20:77–82. doi: 10.1016/S0167-5699(98)01394-2
 39. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A Novel Pathway of Antigen Presentation by Dendritic and Endothelial Cells: Implications for Allorecognition and Infectious Diseases. *Transplantation* (2006) 82:S15–8. doi: 10.1097/01.tp.0000231347.06149.ca
 40. Knight SC, Iqbal S, Roberts MS, Macatonia S, Bedford PA. Transfer of Antigen Between Dendritic Cells in the Stimulation of Primary T Cell Proliferation. *Eur J Immunol* (1998) 28:1636–44. doi: 10.1002/(SICI)1521-4141(199805)28:05<1636::AID-IMMU1636>3.0.CO;2-9
 41. Bestard O, Nickel P, Cruzado JM, Schoenemann C, Boenisch O, Sefrin A, et al. Circulating Alloreactive T Cells Correlate With Graft Function in Longstanding Renal Transplant Recipients. *J Am Soc Nephrol* (2008) 19:1419–29. doi: 10.1681/ASN.2007050539
 42. Oberbarnscheidt MH, Ng YH, Chalasani G. The Roles of CD8 Central and Effector Memory T-Cell Subsets in Allograft Rejection. *Am J Transplant* (2008) 8:1809–18. doi: 10.1111/j.1600-6143.2008.02335.x
 43. Macedo C, Orkis EA, Popescu I, Elinoff BD, Zeevi A, Shapiro R, et al. Contribution of Naive and Memory T-Cell Populations to the Human Alloimmune Response. *Am J Transplant* (2009) 9:2057–66. doi: 10.1111/j.1600-6143.2009.02742.x
 44. Golshayan D, Wyss JC, Buckland M, Hernandez-Fuentes M, Lechler RI. Differential Role of Naive and Memory CD4 T-Cell Subsets in Primary Alloresponses. *Am J Transplant* (2010) 10:1749–59. doi: 10.1111/j.1600-6143.2010.03180.x
 45. Chalasani G, Dai Z, Konieczny BT, Baddoura FK, Lakkis FG. Recall and Propagation of Allospecific Memory T Cells Independent of Secondary Lymphoid Organs. *Proc Natl Acad Sci USA* (2002) 99:6175–80. doi: 10.1073/pnas.092596999
 46. Ni PP, Solomon B, Hsieh CS, Allen PM, Morris GP. The Ability to Rearrange Dual Tcrs Enhances Positive Selection, Leading to Increased Allo- and Autoreactive T Cell Repertoires. *J Immunol* (2014) 193:1778–86. doi: 10.4049/jimmunol.1400532
 47. Schuld NJ, Binstadt BA. Dual TCR T Cells: Identity Crisis or Multitaskers? *J Immunol* (2019) 202:637–44. doi: 10.4049/jimmunol.1800904
 48. Morris GP, Allen PM. Cutting Edge: Highly Alloreactive Dual TCR T Cells Play a Dominant Role in Graft-Versus-Host Disease. *J Immunol* (2009) 182:6639–43. doi: 10.4049/jimmunol.0900638
 49. Morris GP, Uy GL, Donermeyer D, Dipersio JF, Allen PM. Dual Receptor T Cells Mediate Pathologic Alloreactivity in Patients With Acute Graft-Versus-Host Disease. *Sci Transl Med* (2013) 5:188ra74. doi: 10.1126/scitranslmed.3005452
 50. Steger U, Denecke C, Sawitzki B, Karim M, Jones ND, Wood KJ. Exhaustive Differentiation of Alloreactive CD8+ T Cells: Critical for Determination of

- Graft Acceptance or Rejection. *Transplantation* (2008) 85:1339–47. doi: 10.1097/TP.0b013e31816dd64a
51. Sanchez-Fueyo A, Markmann JF. Immune Exhaustion and Transplantation. *Am J Transplant* (2016) 16:1953–7. doi: 10.1111/ajt.13702
 52. Fribourg M, Anderson L, Fischman C, Cantarelli C, Perin L, La Manna G, et al. T-Cell Exhaustion Correlates With Improved Outcomes in Kidney Transplant Recipients. *Kidney Int* (2019) 96:436–49. doi: 10.1016/j.kint.2019.01.040
 53. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells. *Nat Immunol* (2003) 4:330–6. doi: 10.1038/ni904
 54. Mederacke YS, Vondran FW, Kollrich S, Schulde E, Schmitt R, Manns MP, et al. Transient Increase of Activated Regulatory T Cells Early After Kidney Transplantation. *Sci Rep* (2019) 9:1021. doi: 10.1038/s41598-018-37218-x
 55. Taubert R, Danger R, Londono MC, Christakoudi S, Martinez-Picola M, Rimola A, et al. Hepatic Infiltrates in Operational Tolerant Patients After Liver Transplantation Show Enrichment of Regulatory T Cells Before Proinflammatory Genes Are Downregulated. *Am J Transplant* (2016) 16:1285–93. doi: 10.1111/ajt.13617
 56. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. And Promote Immune Reconstitution in HLA-Haploidentical Transplantation. *Blood* (2011) 117:3921–8. doi: 10.1182/blood-2010-10-311894
 57. Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, et al. HLA-Haploidentical Transplantation With Regulatory and Conventional T-Cell Adoptive Immunotherapy Prevents Acute Leukemia Relapse. *Blood* (2014) 124:638–44. doi: 10.1182/blood-2014-03-564401
 58. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion of Ex Vivo Expanded T Regulatory Cells in Adults Transplanted With Umbilical Cord Blood: Safety Profile and Detection Kinetics. *Blood* (2011) 117:1061–70. doi: 10.1182/blood-2010-07-293795
 59. Theil A, Tuve S, Oelschlagel U, Maiwald A, Dohler D, Ossmann D, et al. Adoptive Transfer of Alloeneic Regulatory T Cells Into Patients With Chronic Graft-Versus-Host Disease. *Cytherapy* (2015) 17:473–86. doi: 10.1016/j.jcyt.2014.11.005
 60. Todo S, Yamashita K, Goto R, Zaitu M, Nagatsu A, Oura T, et al. A Pilot Study of Operational Tolerance With a Regulatory T-Cell-Based Cell Therapy in Living Donor Liver Transplantation. *Hepatology* (2016) 64:632–43. doi: 10.1002/hep.28459
 61. Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T Cell Antigen Receptor Recognition of Antigen-Presenting Molecules. *Annu Rev Immunol* (2015) 33:169–200. doi: 10.1146/annurev-immunol-032414-112334
 62. Ferreira LM. Gammadelta T Cells: Innately Adaptive Immune Cells? *Int Rev Immunol* (2013) 32:223–48. doi: 10.3109/08830185.2013.783831
 63. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, et al. Quantitative Characterization of T-Cell Repertoire in Alloeneic Hematopoietic Stem Cell Transplant Recipients. *Bone Marrow Transplant* (2015) 50:1227–34. doi: 10.1038/bmt.2015.133
 64. Wang Y, Singh NK, Spear TT, Hellman LM, Piepenbrink KH, McMahan RH, et al. How an Alloreactive T-Cell Receptor Achieves Peptide and MHC Specificity. *Proc Natl Acad Sci USA* (2017) 114:E4792–801. doi: 10.1073/pnas.1700459114
 65. Krangel MS. Mechanics of T Cell Receptor Gene Rearrangement. *Curr Opin Immunol* (2009) 21:133–9. doi: 10.1016/j.coi.2009.03.009
 66. Jung D, Alt FW. Unraveling V(D)J Recombination; Insights Into Gene Regulation. *Cell* (2004) 116:299–311. doi: 10.1016/S0092-8674(04)00039-X
 67. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A Direct Estimate of the Human Alphabeta T Cell Receptor Diversity. *Science* (1999) 286:958–61. doi: 10.1126/science.286.5441.958
 68. Attaf M, Huseby E, Sewell AK. Alphabeta T Cell Receptors as Predictors of Health and Disease. *Cell Mol Immunol* (2015) 12:391–9. doi: 10.1038/cmi.2014.134
 69. Lu J, Van Laethem F, Bhattacharya A, Craveiro M, Saba I, Chu J, et al. Molecular Constraints on CDR3 for Thymic Selection of MHC-Restricted Tcrs From a Random Pre-Selection Repertoire. *Nat Commun* (2019) 10:1019. doi: 10.1038/s41467-019-08906-7
 70. Sewell AK. Why Must T Cells be Cross-Reactive? *Nat Rev Immunol* (2012) 12:669–77. doi: 10.1038/nri3279
 71. Macdonald WA, Chen Z, Gras S, Archbold JK, Tynan FE, Clements CS, et al. T Cell Allorecognition via Molecular Mimicry. *Immunity* (2009) 31:897–908. doi: 10.1016/j.immuni.2009.09.025
 72. Scott DR, Borbulevych OY, Piepenbrink KH, Corcelli SA, Baker BM. Disparate Degrees of Hypervariable Loop Flexibility Control T-Cell Receptor Cross-Reactivity, Specificity, and Binding Mechanism. *J Mol Biol* (2011) 414:385–400. doi: 10.1016/j.jmb.2011.10.006
 73. Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, et al. T-Cell Receptor (TCR)-Peptide Specificity Overrides Affinity-Enhancing TCR-Major Histocompatibility Complex Interactions. *J Biol Chem* (2014) 289:628–38. doi: 10.1074/jbc.M113.522110
 74. Son ET, Faridi P, Paul-Heng M, Leong ML, English K, Ramarathnam SH, et al. The Self-Peptide Repertoire Plays a Critical Role in Transplant Tolerance Induction. *J Clin Invest* (2021) 131(21):e146771. doi: 10.1172/JCI146771
 75. Elhanati Y, Murugan A, Callan CG Jr, Mora T, Walczak AM. Quantifying Selection in Immune Receptor Repertoires. *Proc Natl Acad Sci USA* (2014) 111:9875–80. doi: 10.1073/pnas.1409572111
 76. Madi A, Poran A, Shifrut E, Reich-Zeliger S, Greenstein E, Zaretsky I, et al. T Cell Receptor Repertoires of Mice and Humans Are Clustered in Similarity Networks Around Conserved Public CDR3 Sequences. *Elife* (2017) 6:e22057. doi: 10.7554/eLife.22057
 77. Stervbo U, Nienen M, Weist BJD, Kuchenbecker L, Hecht J, Wehler P, et al. And T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients. *Front Immunol* (2019) 10:767. doi: 10.3389/fimmu.2019.00767
 78. Corrie BD, Marthandan N, Zimonja B, Jaglale J, Zhou Y, Barr E, et al. Ircceptor: A Platform for Querying and Analyzing Antibody/B-Cell and T-Cell Receptor Repertoire Data Across Federated Repositories. *Immunol Rev* (2018) 284:24–41. doi: 10.1111/imr.12666
 79. Emerson RO, Mathew JM, Konieczna IM, Robins HS, Leventhal JR. Defining the Alloreactive T Cell Repertoire Using High-Throughput Sequencing of Mixed Lymphocyte Reaction Culture. *PLoS One* (2014) 9:e111943. doi: 10.1371/journal.pone.0111943
 80. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, et al. Diversity and Clonal Selection in the Human T-Cell Repertoire. *Proc Natl Acad Sci USA* (2014) 111:13139–44. doi: 10.1073/pnas.1409155111
 81. Zvyagin IV, Pogorelyy MV, Ivanova ME, Komech EA, Shugay M, Bolotin DA, et al. Distinctive Properties of Identical Twins' TCR Repertoires Revealed by High-Throughput Sequencing. *Proc Natl Acad Sci USA* (2014) 111:5980–5. doi: 10.1073/pnas.1319389111
 82. Bettens F, Calderin Sollet Z, Buhler S, Villard J. CD8+ T-Cell Repertoire in Human Leukocyte Antigen Class I-Mismatched Alloreactive Immune Response. *Front Immunol* (2020) 11:588741. doi: 10.3389/fimmu.2020.588741
 83. Wang P, Jin X, Zhou W, Luo M, Xu Z, Xu C, et al. Comprehensive Analysis of TCR Repertoire in COVID-19 Using Single Cell Sequencing. *Genomics* (2021) 113:456–62. doi: 10.1016/j.ygeno.2020.12.036
 84. Briney B, Inderbitzin A, Joyce C, Burton DR. Commonality Despite Exceptional Diversity in the Baseline Human Antibody Repertoire. *Nature* (2019) 566:393–7. doi: 10.1038/s41586-019-0879-y
 85. Wang B, DeKosky BJ, Timm MR, Lee J, Normandin E, Misasi J, et al. Functional Interrogation and Mining of Natively Paired Human VH : VL Antibody Repertoires. *Nat Biotechnol* (2018) 36:152–5. doi: 10.1038/nbt.4052
 86. Faint JM, Pilling D, Akbar AN, Kitas GD, Bacon PA, Salmon M. Quantitative Flow Cytometry for the Analysis of T Cell Receptor Vbeta Chain Expression. *J Immunol Methods* (1999) 225:53–60. doi: 10.1016/S0022-1759(99)00027-7
 87. Salameire D, Le Bris Y, Fabre B, Fauconnier J, Solly F, Pernollet M, et al. Efficient Characterization of the TCR Repertoire in Lymph Nodes by Flow Cytometry. *Cytometry A* (2009) 75:743–51. doi: 10.1002/cyto.a.20767
 88. Cochet M, Pannetier C, Regnault A, Darche S, Leclerc C, Kourilsky P. Molecular Detection and *In Vivo* Analysis of the Specific T Cell Response to a Protein Antigen. *Eur J Immunol* (1992) 22:2639–47. doi: 10.1002/eji.1830221025

89. Correia-Neves M, Waltzinger C, Mathis D, Benoist C. The Shaping of the T Cell Repertoire. *Immunity* (2001) 14:21–32. doi: 10.1016/S1074-7613(01)00086-3
90. Sant'Angelo DB, Lucas B, Waterbury PG, Cohen B, Brabb T, Gorman J, et al. A Molecular Map of T Cell Development. *Immunity* (1998) 9:179–86. doi: 10.1016/S1074-7613(00)80600-7
91. Rechavi E, Lev A, Lee YN, Simon AJ, Yinon Y, Lipitz S, et al. Timely and Spatially Regulated Maturation of B and T Cell Repertoire During Human Fetal Development. *Sci Transl Med* (2015) 7:276ra25. doi: 10.1126/scitranslmed.aaa0072
92. van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten Years of Next-Generation Sequencing Technology. *Trends Genet* (2014) 30:418–26. doi: 10.1016/j.tig.2014.07.001
93. Six A, Mariotti-Ferrandiz ME, Chaara W, Magadan S, Pham HP, Lefranc MP, et al. The Past, Present, and Future of Immune Repertoire Biology - the Rise of Next-Generation Repertoire Analysis. *Front Immunol* (2013) 4:413. doi: 10.3389/fimmu.2013.00413
94. Setliff I, Shiakolas AR, Pilewski KA, Murji AA, Mapengo RE, Janowska K, et al. High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. *Cell* (2019) 179:1636–46.e15. doi: 10.1016/j.cell.2019.11.003
95. Moore C, Gao B, Roskin KM, Vasilescu EM, Addonizio L, Givertz MM, et al. B Cell Clonal Expansion Within Immune Infiltrates in Human Cardiac Allograft Vasculopathy. *Am J Transplant* (2020) 20:1431–8. doi: 10.1111/ajt.15737
96. Dziubianau M, Hecht J, Kuchenbecker L, Sattler A, Stervbo U, Rodelsperger C, et al. TCR Repertoire Analysis by Next Generation Sequencing Allows Complex Differential Diagnosis of T Cell-Related Pathology. *Am J Transplant* (2013) 13:2842–54. doi: 10.1111/ajt.12431
97. Munson DJ, Egelston CA, Chiotti KE, Parra ZE, Bruno TC, Moore BL, et al. Identification of Shared TCR Sequences From T Cells in Human Breast Cancer Using Emulsion RT-PCR. *Proc Natl Acad Sci USA* (2016) 113:8272–7. doi: 10.1073/pnas.1606994113
98. De Simone M, Rossetti G, Pagani M. Single Cell T Cell Receptor Sequencing: Techniques and Future Challenges. *Front Immunol* (2018) 9:1638. doi: 10.3389/fimmu.2018.01638
99. Pasetto A, Lu YC. Single-Cell TCR. And Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy. *Front Immunol* (2021) 12:689091. doi: 10.3389/fimmu.2021.689091
100. Nguyen P, Ma J, Pei D, Obert C, Cheng C, Geiger TL. Identification of Errors Introduced During High Throughput Sequencing of the T Cell Receptor Repertoire. *BMC Genomics* (2011) 12:106. doi: 10.1186/1471-2164-12-106
101. Egorov ES, Merzlyak EM, Shelonov AA, Britanova OV, Sharonov GV, Staroverov DB, et al. Quantitative Profiling of Immune Repertoires for Minor Lymphocyte Counts Using Unique Molecular Identifiers. *J Immunol* (2015) 194:6155–63. doi: 10.4049/jimmunol.1500215
102. Han A, Glanville J, Hansmann L, Davis MM. Linking T-Cell Receptor Sequence to Functional Phenotype at the Single-Cell Level. *Nat Biotechnol* (2014) 32:684–92. doi: 10.1038/nbt.2938
103. Warren RL, Freeman JD, Zeng T, Choe G, Munro S, Moore R, et al. Exhaustive T-Cell Repertoire Sequencing of Human Peripheral Blood Samples Reveals Signatures of Antigen Selection and a Directly Measured Repertoire Size of at Least 1 Million Clonotypes. *Genome Res* (2011) 21:790–7. doi: 10.1101/gr.115428.110
104. Haigh OL, Grant EJ, Nguyen THO, Kedzierska K, Field MA, Miles JJ, et al. Diversity Indices, Physicochemical Properties and CDR3 Motifs Divide Auto-Reactive From Allo-Reactive T-Cell Repertoires. *Int J Mol Sci* (2021) 22(4):1625. doi: 10.3390/ijms22041625
105. Mederacke YS, Nienen M, Jarek M, Geffers R, Hupa-Breier K, Babel N, et al. T Cell Receptor Repertoires Within Liver Allografts Are Different to Those in the Peripheral Blood. *J Hepatol* (2021) 74:1167–75. doi: 10.1016/j.jhep.2020.12.014
106. Habal MV, Miller AMI, Rao S, Lin S, Obradovic A, Khosravi-Maharlooie M, et al. T Cell Repertoire Analysis Suggests a Prominent Bystander Response in Human Cardiac Allograft Vasculopathy. *Am J Transplant* (2021) 21:1465–76. doi: 10.1111/ajt.16333
107. Wu AR, Neff NF, Kalisky T, Dalerba P, Treutlein B, Rothenberg ME, et al. Quantitative Assessment of Single-Cell RNA-Sequencing Methods. *Nat Methods* (2014) 11:41–6. doi: 10.1038/nmeth.2694
108. McDaniel JR, DeKosky BJ, Tanno H, Ellington AD, Georgiou G. Ultra-High-Throughput Sequencing of the Immune Receptor Repertoire From Millions of Lymphocytes. *Nat Protoc* (2016) 11:429–42. doi: 10.1038/nprot.2016.024
109. Redmond D, Poran A, Elemento O. Single-Cell Tcrseq: Paired Recovery of Entire T-Cell Alpha and Beta Chain Transcripts in T-Cell Receptors From Single-Cell Rnaseq. *Genome Med* (2016) 8:80. doi: 10.1186/s13073-016-0335-7
110. Shalek AK, Satija R, Adiconis X, Gertner RS, Gaublomme JT, Raychowdhury R, et al. Single-Cell Transcriptomics Reveals Bimodality in Expression and Splicing in Immune Cells. *Nature* (2013) 498:236–40. doi: 10.1038/nature12172
111. Ziegenhain C, Vieth B, Parekh S, Reinius B, Guillaumet-Adkins A, Smets M, et al. Comparative Analysis of Single-Cell RNA Sequencing Methods. *Mol Cell* (2017) 65:631–43.e4. doi: 10.1016/j.molcel.2017.01.023
112. Trapnell C. Defining Cell Types and States With Single-Cell Genomics. *Genome Res* (2015) 25:1491–8. doi: 10.1101/gr.190595.115
113. Kim SM, Bhonsle L, Besgen P, Nickel J, Backes A, Held K, et al. Analysis of the Paired TCR Alpha- and Beta-Chains of Single Human T Cells. *PLoS One* (2012) 7:e37338. doi: 10.1371/journal.pone.0037338
114. Spindler MJ, Nelson AL, Wagner EK, Oppermans N, Bridgeman JS, Heather JM, et al. Massively Parallel Interrogation and Mining of Natively Paired Human Tcralphabeta Repertoires. *Nat Biotechnol* (2020) 38:609–19. doi: 10.1038/s41587-020-0438-y
115. Mahe E, Pugh T, Kamel-Reid S. T Cell Clonality Assessment: Past, Present and Future. *J Clin Pathol* (2018) 71:195–200. doi: 10.1136/jclinpath-2017-204761
116. Fu J, Zuber J, Shonts B, Obradovic A, Wang Z, Frangaj K, et al. Lymphohematopoietic Graft-Versus-Host Responses Promote Mixed Chimerism in Patients Receiving Intestinal Transplantation. *J Clin Invest* (2011) 131(8):e141698. doi: 10.1172/JCI141698
117. Zuber J, Shonts B, Lau SP, Obradovic A, Fu J, Yang S, et al. Bidirectional Intragraft Alloreactivity Drives the Repopulation of Human Intestinal Allografts and Correlates With Clinical Outcome. *Sci Immunol* (2016) 1(4):eah3732. doi: 10.1126/sciimmunol.aah3732
118. Savage TM, Shonts BA, Lau S, Obradovic A, Robins H, Shaked A, et al. Deletion of Donor-Reactive T Cell Clones After Human Liver Transplant. *Am J Transplant* (2020) 20:538–45. doi: 10.1111/ajt.15592
119. Brouard S, Dupont A, Giral M, Louis S, Lair D, Braudeau C, et al. Operationally Tolerant and Minimally Immunosuppressed Kidney Recipients Display Strongly Altered Blood T-Cell Clonal Regulation. *Am J Transplant* (2005) 5:330–40. doi: 10.1111/j.1600-6143.2004.00700.x
120. Miqueu P, Degauque N, Guillet M, Giral M, Ruiz C, Pallier A, et al. Analysis of the Peripheral T-Cell Repertoire in Kidney Transplant Patients. *Eur J Immunol* (2010) 40:3280–90. doi: 10.1002/eji.201040301
121. Roussey-Kesler G, Giral M, Moreau A, Subra JF, Legendre C, Noel C, et al. Clinical Operational Tolerance After Kidney Transplantation. *Am J Transplant* (2006) 6:736–46. doi: 10.1111/j.1600-6143.2006.01280.x
122. Yap M, Boeffard F, Clave E, Pallier A, Danger R, Giral M, et al. Expansion of Highly Differentiated Cytotoxic Terminally Differentiated Effector Memory CD8+ T Cells in a Subset of Clinically Stable Kidney Transplant Recipients: A Potential Marker for Late Graft Dysfunction. *J Am Soc Nephrol* (2014) 25:1856–68. doi: 10.1681/ASN.2013080848
123. Morris H, DeWolf S, Robins H, Sprangers B, LoCascio SA, Shonts BA, et al. Tracking Donor-Reactive T Cells: Evidence for Clonal Deletion in Tolerant Kidney Transplant Patients. *Sci Transl Med* (2015) 7:272ra10. doi: 10.1126/scitranslmed.3010760
124. Alachkar H, Mutonga M, Kato T, Kalluri S, Kakuta Y, Uemura M, et al. Quantitative Characterization of T-Cell Repertoire and Biomarkers in Kidney Transplant Rejection. *BMC Nephrol* (2016) 17:181. doi: 10.1186/s12882-016-0395-3
125. Han FF, Fan H, Ren LL, Wang HG, Wang C, Ma X, et al. Profiling the Pattern of Human TRB/IGH-CDR3 Repertoire in Liver Transplantation Patients via High-Throughput Sequencing Analysis. *Scand J Immunol* (2020) 92:e12912. doi: 10.1111/sji.12912

126. Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, et al. Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-Versus-Host Disease Tissues. *Biol Blood Marrow Transplant* (2019) 25:417–23. doi: 10.1016/j.bbmt.2018.10.012
127. Margolis DA, Casper JT, Segura AD, Janczak T, McOlash L, Fisher B, et al. Infiltrating T Cells During Liver Graft-Versus-Host Disease Show a Restricted T-Cell Repertoire. *Biol Blood Marrow Transplant: J Am Soc Blood Marrow Transplant* (2000) 6:408–15. doi: 10.1016/S1083-8791(00)70017-6
128. Kanakry CG, Coffey DG, Towlerton AMH, Vulic A, Storer BE, Chou J, et al. Origin and Evolution of the T Cell Repertoire After Posttransplantation Cyclophosphamide. *JCI Insight* (2016) 1(5):e86252. doi: 10.1172/jci.insight.86252
129. Hirokawa M, Matsutani T, Saitoh H, Ichikawa Y, Kawabata Y, Horiuchi T, et al. And TCRBV Repertoire and CDR3 Sequence of T Lymphocytes Clonally Expanded in Blood and GVHD Lesions After Human Allogeneic Bone Marrow Transplantation. *Bone Marrow Transplant* (2002) 30:915–23. doi: 10.1038/sj.bmt.1703730
130. Beck RC, Wlodarski M, Gondek L, Theil KS, Tuthill RJ, Sobeck R, et al. Efficient Identification of T-Cell Clones Associated With Graft-Versus-Host Disease in Target Tissue Allows for Subsequent Detection in Peripheral Blood. *Br J Haematol* (2005) 129:411–9. doi: 10.1111/j.1365-2141.2005.05472.x
131. Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, et al. Lineage Tracking Reveals Dynamic Relationships of T Cells in Colorectal Cancer. *Nature* (2018) 564:268–72. doi: 10.1038/s41586-018-0694-x
132. Cui JH, Lin KR, Yuan SH, Jin YB, Chen XP, Su XK, et al. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer. *Front Immunol* (2018) 9:2729. doi: 10.3389/fimmu.2018.02729
133. Michálek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and Monitoring of Graft-Versus-Host Specific T-Cell Clone in Stem Cell Transplantation. *Lancet* (2003) 361:1183–5. doi: 10.1016/S0140-6736(03)12917-0
134. Fu J, Zuber J, Martinez M, Shonts B, Obradovic A, Wang H, et al. Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells That Are Maintained by a Circulating Pool. *Cell Stem Cell* (2019) 24:227–39.e8. doi: 10.1016/j.stem.2018.11.007
135. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) Is Essential for the Surface Expression of Latent TGF- β on Platelets and Activated FOXP3+ Regulatory T Cells. *Proc Natl Acad Sci USA* (2009) 106:13445–50. doi: 10.1073/pnas.0901944106
136. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, et al. Direct Access to CD4+ T Cells Specific for Defined Antigens According to CD154 Expression. *Nat Med* (2005) 11:1118–24. doi: 10.1038/nm1292
137. Giudicelli V, Chaume D, Lefranc MP. IMGT/GENE-DB: A Comprehensive Database for Human and Mouse Immunoglobulin and T Cell Receptor Genes. *Nucleic Acids Res* (2005) 33:D256–61. doi: 10.1093/nar/gki010
138. Shugay M, Bagaev DV, Zvyagin IV, Vroomans RM, Crawford JC, Dolton G, et al. Vdjdb: A Curated Database of T-Cell Receptor Sequences With Known Antigen Specificity. *Nucleic Acids Res* (2018) 46:D419–27. doi: 10.1093/nar/gkx760
139. Tickotsky N, Sagiv T, Prilusky J, Shifrut E, Friedman N. Mpcas-TCR: A Manually Curated Catalogue of Pathology-Associated T Cell Receptor Sequences. *Bioinf (Oxford England)* (2017) 33:2924–9. doi: 10.1093/bioinformatics/btx286
140. Li S, Lefranc MP, Miles JJ, Alamyar E, Giudicelli V, Duroux P, et al. IMGT/HighV QUEST Paradigm for T Cell Receptor IMGT Clonotype Diversity and Next Generation Repertoire Immunoprofiling. *Nat Commun* (2013) 4:2333. doi: 10.1038/ncomms3333
141. Bagaev DV, Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G, et al. Vdjdb in 2019: Database Extension, New Analysis Infrastructure and a T-Cell Receptor Motif Compendium. *Nucleic Acids Res* (2020) 48:D1057–62. doi: 10.1093/nar/gkz874
142. Christley S, Scarborough W, Salinas E, Rounds WH, Toby IT, Fonner JM, et al. Vdjsrver: A Cloud-Based Analysis Portal and Data Commons for Immune Repertoire Sequences and Rearrangements. *Front Immunol* (2018) 9:976. doi: 10.3389/fimmu.2018.00976
143. Rubelt F, Busse CE, Bukhari SAC, Bürckert J-P, Mariotti-Ferrandiz E, Cowell LG, et al. Adaptive Immune Receptor Repertoire Community Recommendations for Sharing Immune-Repertoire Sequencing Data. *Nat Immunol* (2017) 18:1274–8. doi: 10.1038/ni.3873
144. Looney TJ, Topacio-Hall D, Lowman G, Conroy J, Morrison C, Oh D, et al. TCR Convergence in Individuals Treated With Immune Checkpoint Inhibition for Cancer. *Front Immunol* (2019) 10:2985. doi: 10.3389/fimmu.2019.02985
145. Dash P, Fiore-Gartland AJ, Hertz T, Wang GC, Sharma S, Souquette A, et al. Quantifiable Predictive Features Define Epitope-Specific T Cell Receptor Repertoires. *Nature* (2017) 547:89–93. doi: 10.1038/nature22383
146. Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM. Analyzing the Mycobacterium Tuberculosis Immune Response by T-Cell Receptor Clustering With GLIPH2 and Genome-Wide Antigen Screening. *Nat Biotechnol* (2020) 38:1194–202. doi: 10.1038/s41587-020-0505-4
147. Zhang H, Zhan X, Li B. GIANA Allows Computationally-Efficient TCR Clustering and Multi-Disease Repertoire Classification by Isometric Transformation. *Nat Commun* (2021) 12:4699. doi: 10.1038/s41467-021-25006-7
148. Glanville J, Huang H, Nau A, Hatton O, Wagar LE, Rubelt F, et al. Identifying Specificity Groups in the T Cell Receptor Repertoire. *Nature* (2017) 547:94–8. doi: 10.1038/nature22976
149. Zhang W, Hawkins PG, He J, Gupta NT, Liu J, Choonoo G, et al. A Framework for Highly Multiplexed Dextramer Mapping and Prediction of T Cell Receptor Sequences to Antigen Specificity. *Sci Adv* (2021) 7. doi: 10.1126/sciadv.abf5835

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tian, Li and Lv. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.